Physicians must advise patients to prevent use of all phosphodiesterase form 5 (PDE5) inhibitors, which includes LEVITRA, and request professional medical consideration in the occasion of unexpected lack of eyesight in a single or equally eyes. These kinds of an occasion could be a signal of nonarteritic anterior ischemic optic neuropathy (NAION),